Annovis Bio(ANVS) - 2024 Q4 - Annual Results

Clinical Trials and Research Advancements - In 2024, Annovis advanced the buntanetap program, completing two clinical trials: Phase 2/3 for Alzheimer's disease (AD) and Phase 3 for Parkinson's disease (PD) with promising results[2]. - Annovis launched a pivotal Phase 3 AD study in February 2025, with symptomatic data expected in mid-2026 and disease-modifying data in mid-2027[5]. - The company appointed Matthew Peterson, Ph.D., as Senior Clinical Scientist in October 2024 to oversee clinical trials[5]. Financial Performance - Annovis reported a basic and diluted net loss per share of $0.43 for Q4 2024, significantly improved from a loss of$2.24 per share in Q4 2023[5]. - The company reported a net loss of $5.9 million for Q4 2024, a significant reduction from a loss of$22.2 million in Q4 2023[13]. - For the full year 2024, research and development expenses totaled $20.0 million, down 48.5$38.8 million in 2023[5]. - Research and development expenses for Q4 2024 were $5.0 million, a decrease of 43.3$8.9 million in Q4 2023[5]. Assets and Equity - The company had cash and cash equivalents of $10.6 million as of December 31, 2024, an increase from$5.8 million as of December 31, 2023[5]. - Annovis' total assets increased to $13.9 million as of December 31, 2024, compared to$10.2 million in 2023[11]. - Annovis' total stockholders' equity improved to $9.3 million as of December 31, 2024, compared to a deficit of$7.8 million in 2023[11].